Insider Buying Sparks Buzz: Recent posts on X have been abuzz with news of significant insider purchases at Alumis Inc., with reports of a director acquiring shares worth millions in the past few days. Many are interpreting this as a strong vote of confidence in the company’s future. This activity has coincided with a noticeable uptick in the stock price, fueling further chatter.
Clinical Catalysts in Focus: Discussions on X also highlight anticipation for upcoming clinical data releases related to treatments for psoriasis and lupus, expected in 2026. Some users are pointing to these potential milestones as key drivers for long-term interest. The sentiment around these developments appears to be generating cautious optimism among the community.
Note: This discussion summary was generated from an AI condensation of post data.
Alumis Inc. Insider Trading Activity
Alumis Inc. insiders have traded $ALMS stock on the open market 16 times in the past 6 months. Of those trades, 16 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ALMS stock by insiders over the last 6 months:
- JAMES B. TANANBAUM has made 4 purchases buying 507,874 shares for an estimated $3,094,725 and 0 sales.
- CAPITAL MANAGEMENT VI LLC FORESITE has made 4 purchases buying 507,874 shares for an estimated $3,094,725 and 0 sales.
- LABS, LLC FORESITE has made 4 purchases buying 507,874 shares for an estimated $3,094,725 and 0 sales.
- SRINIVAS AKKARAJU has made 4 purchases buying 517,517 shares for an estimated $2,979,804 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Alumis Inc. Hedge Fund Activity
We have seen 62 institutional investors add shares of Alumis Inc. stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WOODLINE PARTNERS LP added 1,558,660 shares (+809.7%) to their portfolio in Q3 2025, for an estimated $6,219,053
- MADISON AVENUE PARTNERS, LP removed 1,424,492 shares (-77.3%) from their portfolio in Q3 2025, for an estimated $5,683,723
- TANG CAPITAL MANAGEMENT LLC removed 829,788 shares (-41.6%) from their portfolio in Q3 2025, for an estimated $3,310,854
- VELAN CAPITAL INVESTMENT MANAGEMENT LP removed 674,163 shares (-41.6%) from their portfolio in Q3 2025, for an estimated $2,689,910
- VANGUARD GROUP INC added 625,404 shares (+18.4%) to their portfolio in Q3 2025, for an estimated $2,495,361
- CANTOR FITZGERALD, L. P. removed 559,201 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,231,211
- UBS GROUP AG removed 444,880 shares (-36.8%) from their portfolio in Q3 2025, for an estimated $1,775,071
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Alumis Inc. Analyst Ratings
Wall Street analysts have issued reports on $ALMS in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 08/15/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/14/2025
- Wells Fargo issued a "Overweight" rating on 07/25/2025
- Guggenheim issued a "Buy" rating on 06/10/2025
To track analyst ratings and price targets for Alumis Inc., check out Quiver Quantitative's $ALMS forecast page.
Alumis Inc. Price Targets
Multiple analysts have issued price targets for $ALMS recently. We have seen 5 analysts offer price targets for $ALMS in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $22.0 on 08/15/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $14.0 on 08/14/2025
- Derek Archila from Wells Fargo set a target price of $17.0 on 07/25/2025
- Yatin Suneja from Guggenheim set a target price of $18.0 on 06/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
